**Joaquin E. Cigarroa, MD, FACC**
**Professor of Medicine, Director Knight CV Institute, Division Head of Cardiovascular Medicine**
Oregon Health & Science University (IC)

**Printed as of 11/20/2026**

# Disclosures

## Personal Commercial (0)

No disclosures on record

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (7)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | *Topic Area(s)* |
|---|---|---|---|
| ***Self*** | | | |
| ACC NCDR Science and Quality Committee Chair | Other - *ACC Committee* | None ($0) | *Other* |
| AHA, Board of Directors, Western Affiliate (ended in 2018 or 2019) | Officer, Director, Trustee, or other Fiduciary Role | None ($0) | *General Cardiology* |
| American Stroke Association, Cyrptogenic Stroke Initiative Advisory Committee | Other | None ($0) | |
| Catheterization and Cardiovascular Intervention | Other - *Deputy Editor* | Significant (>= $5,000) | *Invasive CV Angio and Interventions* |
| FDA Circulatory Devices Panel Chair (July 1, 2022-<br>*† none* | Other - *Chair of the Circulatory Devices Panel* | Modest (< $5,000) | |
| SCAI DEI Committee Chair, Government Relations Co-chair Ended May 2o24 | Other - *Committee Chair* | None ($0) | *Invasive CV Angio and Interventions* |
| SCAI: Board of Trustees and Vice President 2025 to May 2026 | Officer, Director, Trustee, or other Fiduciary Role | None ($0) | *Invasive CV Angio and Interventions* |

## Clinical Trial Enroller (1)

| Trial Name | Trial Sponsor | Trial Funding Source |
|---|---|---|
| Ischemia Trial | National Institutes of Health | |

## Institutional Financial Decision-Making Role (1)

| Funding Source | Institutional Compensation Level |
|---|---|
| Chief of Cardiology and Director of Knight CV Institute, OHSU | Significant (>= $5,000) |

## Expert Witness Testimony (3)

| Year | Case Title | Represented | Description | Compensation |
|---|---|---|---|---|
| ***Self*** | | | | |
| 2021 | Cardiac Arrest | Defendant | Patient experienced cardiac arrest after lidocaine injection and expired despite CPR/hospitalization due to anoxic brain injury | None ($0) |
| 2011 | Coronary artery disease review | Defendant | review of documents for defendant | Modest (< $5,000) |
| 2010 | Sudden death/coronary artery disease. | Defendant | Patient with stable angina who experienced sudden death on aspirin therapy prior to noninvasive risk stratification. | Modest (< $5,000) |

*† Commercial Funding Source | ‡ Trial Name*

# Agreement

**Certified Education Attestation** | Signed on 9/22/2025
*URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 9/22/2025
*URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement*

**Embargo** | Signed on 9/22/2025

*URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement*

**On-Going Obligation Agreement** | Signed on 9/22/2025

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.